JP2007510622A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2007510622A5 JP2007510622A5 JP2006534362A JP2006534362A JP2007510622A5 JP 2007510622 A5 JP2007510622 A5 JP 2007510622A5 JP 2006534362 A JP2006534362 A JP 2006534362A JP 2006534362 A JP2006534362 A JP 2006534362A JP 2007510622 A5 JP2007510622 A5 JP 2007510622A5
- Authority
- JP
- Japan
- Prior art keywords
- antibody
- gene
- chain gene
- vie
- vib
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US50947303P | 2003-10-08 | 2003-10-08 | |
| PCT/US2004/033176 WO2005034733A2 (en) | 2003-10-08 | 2004-10-08 | Methods and compositions for diagnosis and treatment of b cell chronic lymphocytic leukemia |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2007510622A JP2007510622A (ja) | 2007-04-26 |
| JP2007510622A5 true JP2007510622A5 (cg-RX-API-DMAC7.html) | 2007-11-22 |
Family
ID=34434984
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2006534362A Pending JP2007510622A (ja) | 2003-10-08 | 2004-10-08 | B細胞慢性リンパ性白血病の診断及び治療のための方法及び組成物 |
Country Status (6)
| Country | Link |
|---|---|
| US (2) | US8119340B2 (cg-RX-API-DMAC7.html) |
| EP (1) | EP1678195A4 (cg-RX-API-DMAC7.html) |
| JP (1) | JP2007510622A (cg-RX-API-DMAC7.html) |
| AU (1) | AU2004279441B2 (cg-RX-API-DMAC7.html) |
| CA (1) | CA2541360A1 (cg-RX-API-DMAC7.html) |
| WO (1) | WO2005034733A2 (cg-RX-API-DMAC7.html) |
Families Citing this family (34)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AR045563A1 (es) | 2003-09-10 | 2005-11-02 | Warner Lambert Co | Anticuerpos dirigidos a m-csf |
| CA2541360A1 (en) | 2003-10-08 | 2005-04-21 | Bradley T. Messmer | Methods and compositions for diagnosis and treatment of b cell chronic lymphocytic leukemia |
| US20070105165A1 (en) * | 2005-11-04 | 2007-05-10 | Charles Goolsby | Composite profiles of cell antigens and target signal transduction proteins for analysis and clinical management of hematologic cancers |
| US7767206B2 (en) * | 2006-10-02 | 2010-08-03 | Amgen Inc. | Neutralizing determinants of IL-17 Receptor A and antibodies that bind thereto |
| TW200918553A (en) * | 2007-09-18 | 2009-05-01 | Amgen Inc | Human GM-CSF antigen binding proteins |
| AR072999A1 (es) | 2008-08-11 | 2010-10-06 | Medarex Inc | Anticuerpos humanos que se unen al gen 3 de activacion linfocitaria (lag-3) y los usos de estos |
| IL299365A (en) | 2010-05-27 | 2023-02-01 | Genmab As | Monoclonal antibodies against 2HER |
| NZ604007A (en) | 2010-05-27 | 2015-03-27 | Genmab As | Monoclonal antibodies against her2 epitope |
| EP3957653A1 (en) * | 2010-06-02 | 2022-02-23 | Dana Farber Cancer Institute, Inc. | Humanized monoclonal antibodies and methods of use |
| WO2012143524A2 (en) | 2011-04-20 | 2012-10-26 | Genmab A/S | Bispecific antibodies against her2 and cd3 |
| US9175082B2 (en) | 2012-05-31 | 2015-11-03 | Sorrento Therapeutics, Inc. | Antigen binding proteins that bind PD-L1 |
| AR091649A1 (es) | 2012-07-02 | 2015-02-18 | Bristol Myers Squibb Co | Optimizacion de anticuerpos que se fijan al gen de activacion de linfocitos 3 (lag-3) y sus usos |
| DE102012212025A1 (de) * | 2012-07-10 | 2014-01-16 | Osram Gmbh | Leuchtmodul |
| EP2741084B1 (en) | 2012-12-07 | 2020-01-22 | AVA Lifescience GmbH | Method of prognosing the clinical course of chronic lymphocytic leukemia (CLL) |
| JP2016507520A (ja) | 2013-01-23 | 2016-03-10 | ザ ボード オブ トラスティーズ オブ ザ レランド スタンフォード ジュニア ユニバーシティー | 安定化されたb型肝炎コアポリペプチド |
| RS64268B1 (sr) | 2013-09-20 | 2023-07-31 | Bristol Myers Squibb Co | Kombinacija anti-lag-3 antitela i anti-pd-1 antitela za lečenje tumora |
| UA122479C2 (uk) | 2014-01-24 | 2020-11-25 | Дана-Фарбер Кенсер Інстітьют, Інк. | Виділена молекула антитіла, яка зв’язується з людським білком програмованої смерті-1 (pd-1) |
| EA201691765A1 (ru) | 2014-03-14 | 2016-12-30 | Новартис Аг | Молекулы антител против lag-3 и их применения |
| US9976146B2 (en) * | 2014-05-30 | 2018-05-22 | Academia Sinica | Aptamer targeting MAGE-A3 peptide and uses thereof |
| US20180340025A1 (en) | 2015-07-29 | 2018-11-29 | Novartis Ag | Combination therapies comprising antibody molecules to lag-3 |
| WO2017023859A1 (en) * | 2015-07-31 | 2017-02-09 | Memorial Sloan-Kettering Cancer Center | Antigen-binding proteins targeting cd56 and uses thereof |
| US20170073397A1 (en) * | 2015-08-24 | 2017-03-16 | Medimmune, Llc | MrkA Polypeptides, Antibodies, and Uses Thereof |
| AU2016319126A1 (en) | 2015-09-10 | 2018-04-19 | Affigen, Inc. | Sequencing-directed selection of tumor theranostics |
| CN108495651A (zh) | 2015-12-17 | 2018-09-04 | 诺华股份有限公司 | 抗pd-1的抗体分子及其用途 |
| US10836810B2 (en) | 2017-02-17 | 2020-11-17 | Mapp Biopharmaceutical, Inc. | Monoclonal antibodies and cocktails for treatment of ebola infections |
| WO2018222718A1 (en) | 2017-05-30 | 2018-12-06 | Bristol-Myers Squibb Company | Treatment of lag-3 positive tumors |
| JP7301002B2 (ja) | 2017-05-30 | 2023-06-30 | ブリストル-マイヤーズ スクイブ カンパニー | 抗lag-3抗体または抗lag-3抗体および抗pd-1もしくは抗pd-l1抗体を含む組成物 |
| CN109752548B (zh) * | 2019-02-01 | 2022-05-06 | 广州金域医学检验中心有限公司 | 评估慢性淋巴细胞白血病预后的组合试剂及系统 |
| US12378321B2 (en) | 2019-03-08 | 2025-08-05 | Memorial Sloan Kettering Cancer Center | ADAM17 binding molecules and uses thereof |
| EP4013794A4 (en) | 2019-08-12 | 2023-11-22 | City of Hope | ANTI-IL1RAP ANTIBODIES |
| CA3196496A1 (en) | 2020-10-23 | 2022-04-28 | Laurence David TOMS | Lag-3 antagonist therapy for lung cancer |
| EP4341289A1 (en) * | 2021-05-18 | 2024-03-27 | Christian-Albrechts-Universität zu Kiel | Co-stimulatory multispecific antibodies |
| CN113461818B (zh) * | 2021-06-30 | 2022-01-21 | 徐州医科大学 | 靶向CD276的全人源抗体scFv、嵌合抗原受体、工程化免疫细胞及其制备方法 |
| AU2023231622A1 (en) * | 2022-03-07 | 2024-09-26 | Agenus Inc. | Anti-ilt2 antibodies and uses thereof |
Family Cites Families (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5530101A (en) * | 1988-12-28 | 1996-06-25 | Protein Design Labs, Inc. | Humanized immunoglobulins |
| EP2270049A3 (en) * | 2002-04-12 | 2011-03-09 | Medimmune, Inc. | Recombinant anti-interleukin-9-antibody |
| CA2541360A1 (en) | 2003-10-08 | 2005-04-21 | Bradley T. Messmer | Methods and compositions for diagnosis and treatment of b cell chronic lymphocytic leukemia |
-
2004
- 2004-10-08 CA CA002541360A patent/CA2541360A1/en not_active Abandoned
- 2004-10-08 EP EP04794503A patent/EP1678195A4/en not_active Withdrawn
- 2004-10-08 WO PCT/US2004/033176 patent/WO2005034733A2/en not_active Ceased
- 2004-10-08 JP JP2006534362A patent/JP2007510622A/ja active Pending
- 2004-10-08 AU AU2004279441A patent/AU2004279441B2/en not_active Ceased
- 2004-10-08 US US10/575,671 patent/US8119340B2/en active Active
-
2012
- 2012-01-20 US US13/354,774 patent/US9745364B2/en not_active Expired - Fee Related
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Grisaru-Tal et al. | Metastasis-entrained eosinophils enhance lymphocyte-mediated antitumor immunity | |
| Ghia et al. | Ordering of human bone marrow B lymphocyte precursors by single-cell polymerase chain reaction analyses of the rearrangement status of the immunoglobulin H and L chain gene loci | |
| Ghia et al. | Chronic lymphocytic leukemia | |
| Keerthivasan et al. | β-Catenin promotes colitis and colon cancer through imprinting of proinflammatory properties in T cells | |
| Milstein et al. | Monoclonal antibodies and cell surface antigens | |
| Safarzadeh Kozani et al. | In like a lamb; out like a lion: marching CAR T cells toward enhanced efficacy in B-ALL | |
| Tjandra et al. | Progressive development of a Th1‐type hepatic cytokine profile in rats with experimental cholangitis | |
| JP2009539841A5 (cg-RX-API-DMAC7.html) | ||
| CN111148514A (zh) | 与免疫调节剂联合应用于癌症免疫治疗的rar选择性激动剂 | |
| JP2007510622A (ja) | B細胞慢性リンパ性白血病の診断及び治療のための方法及び組成物 | |
| Freria et al. | Serial systemic injections of endotoxin (LPS) elicit neuroprotective spinal cord microglia through IL-1-dependent cross talk with endothelial cells | |
| Iwata et al. | Egr2 drives the differentiation of Ly6Chi monocytes into fibrosis-promoting macrophages in metabolic dysfunction-associated steatohepatitis in mice | |
| JP2008508858A5 (cg-RX-API-DMAC7.html) | ||
| Xiang et al. | ROS-activated CXCR2+ neutrophils recruited by CXCL1 delay denervated skeletal muscle atrophy and undergo P53-mediated apoptosis | |
| Herberman | Mechanisms of cytotoxicity by NK cells | |
| JP2018522061A5 (cg-RX-API-DMAC7.html) | ||
| JP2021535100A (ja) | M2マクロファージ極性化を調節する方法及び治療におけるその使用 | |
| Atherton et al. | Bite-size introduction to canine hematologic malignancies | |
| Guo et al. | GPR116 receptor regulates the antitumor function of NK cells via Gαq/HIF1α/NF-κB signaling pathway as a potential immune checkpoint | |
| Ikezumi et al. | The role of lymphocytes in the experimental progressive glomerulonephritis | |
| JP2008538173A5 (cg-RX-API-DMAC7.html) | ||
| Demireva et al. | Creation of the 5-hydroxytryptamine receptor 7 knockout rat as a tool for cardiovascular research | |
| JP2008522162A5 (cg-RX-API-DMAC7.html) | ||
| Feeney et al. | Terminal deoxynucleotidyl transferase deficiency decreases autoimmune disease in MRL-Fas lpr mice | |
| Dang et al. | Cutting edge: regulation of uterine NKT cells by a fetal class I molecule other than CD1 |